Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Proactive Investors Australia CEO Sessions and Wholesale Investor's Emergence 2019
16 slides from Anatara Lifesciences's conference presentation, Feb 19, 2019
Slide 1: ASX Release: Anatara Investor Presentation
ASX Release Anatara Investor Presentation For personal use only BRISBANE & MELBOURNE, 19th February 2019: Anatara Lifesciences (ASX:ANR) is pleased to release a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will be presenting at the Proactive Investors Australia CEO Ses
Slide 2: Bringing Science to Supplements
For personal use only Bringing Science to Supplements February 2019
Slide 3: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 4: Key Investor Message
Key Investor Message For personal use only Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health 3
Slide 5: Key Financial Details
Key Financial Details For personal use only ASX Code Market Share Price1 ANR Capitalisation1 $24.7 million $0.50 Current Cash2 Ordinary Shares Options $6.0 million 49,413,236 2,346,000 • ~$1.25m R&D tax refund received for 2017-18 activities • Sufficiently funded to execute on the development and pa
Slide 6: Company Highlights
Company Highlights • Detach (exclusive global license to Zoetis Inc.) For personal use only • APVMA approved for use in piglets • Key appointments with significant human health experience • Sue MacLeman, Dr Jane Ryan, Dr David Brookes, Steve Lydeamore • First human product candidate • Gastrointestin
Slide 7: Animal Health
Animal Health • Detach is a natural, safe, non-antibiotic product that aids For personal use only in the control of diarrhoea (known as scour) in livestock • In May 2018, Anatara signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide dev
Slide 8: From animals to humans
For personal use only From animals to humans
Slide 9: Market Opportunity
Market Opportunity Irritable Bowel Syndrome Inflammatory Bowel Disease For personal use only (IBS) (IBD) Affects around 11% of the global population4 >5 million sufferers globally6 ~50% of patients5 turn to dietary supplements 30-50% of IBD patients7 turn to and complementary medicines complementary
Slide 10: Patient Story
Patient Story For personal use only • You will now hear from patient, Adam, who is living with IBS and the impact the condition has had on his life. Adam highlights his most difficult symptoms to manage and his own experiences with the effectiveness of current therapies and management practices. 9
Slide 11: Gastrointestinal ReProgramming (GaRP) Dietary Supplement
Gastrointestinal ReProgramming (GaRP) Dietary Supplement For personal use only How does it work? GaRP is a microbiome-targeted dietary supplement aimed at: Correcting Alleviation of gut microbiota the Repair of gut to restore Reduction of symptomatic lining and normal inflammation diarrhoea barrier
Slide 12: Scientifically Proven
Scientifically Proven For personal use only Successful Proof of Concept Studies • Potential breakthrough dietary product • Anatara’s proprietary GaRP formulation was9 efficacious and: • Reduced production of pro- inflammatory proteins by gut and inflammatory cells by >85%; • Reduced the attachment a
Slide 13: Dual targeted product combining bromelain and GRAS components
Dual targeted product combining bromelain and other GRAS For personal use only components Ileum targeted components • prevent attachment of pro-inflammatory bacteria • restore gut microbiota • reduce inflammation Colon targeted components • restore gut microbiota Ileum • reduce inflammation • mucosa
Slide 14: Advantages of Dietary Supplements
Advantages of Dietary Supplements* The advantages of a dietary supplement regulatory For personal use only strategy are: Fewer or lower regulatory requirements than pharmaceuticals10 ->Lower development cost ->Lower development risk ->Faster time to market Rapid market penetration11 Public and healt
Slide 15: Clear Path to Commercialisation
Clear Path to Commercialisation 2017 2017 2018 2018 2019 2019 2020 2020 For personal use only H1 H2 H1 H2 H1 H2 H1 H2 Confirmed GRAS status for components with FDA Established collaboration with University of Liverpool (UK) Completed product development plan Patent Application filed Commerci
Slide 16: Anatara Lifesciences Ltd Summary
Anatara Lifesciences Ltd (ASX:ANR) Summary • Innovative, evidence-based products, backed by scientific and For personal use only clinical studies for gastrointestinal health • GaRP dietary supplement seeks to target IBS and IBD patients • Patentable multi-component, dual-targeted formulation • Deliv